Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator

A method of treating a patient suffering from hypercortisolemia, and a symptom or comorbidity thereof, the method comprising administering to the subject an effective amount of a nonsteroidal selective glucocorticoid receptor modulator (selective GRM) having a heteroaryl-ketone fused azadecalin structure or a nonsteroidal selective GRM having an octahydro fused azadecalin structure, effective to treat said symptom or comorbidity of hypercortisolemia, wherein said symptom or comorbidity of hypercortisolemia is one or more of:

• hyperglycemia, wherein said treatment is effective to significantly lower the patient's AUCglucose as compared to the patient's baseline AUCglucose measured prior to treatment;
• hypertension, wherein said treatment is effective to significantly lower the patient's blood pressure as compared to the patient's baseline blood pressure measured prior to treatment;
• an abnormal liver enzyme level, wherein said treatment is effective to significantly lower an abnormal patient liver enzyme level as compared to the patient's baseline liver enzyme level measured prior to treatment;
• an abnormal fructosamine level, wherein said treatment is effective to significantly improve an abnormal patient fructosamine level as compared to the patient's baseline fructosamine level measured prior to treatment;
• an abnormal serum osteocalcin level, wherein said treatment is effective to significantly improve an abnormal patient serum osteocalcin level as compared to the patient's baseline serum osteocalcin level measured prior to treatment;
• an abnormal heartbeat interval or median heart rate, wherein said treatment is effective to significantly improve an abnormal patient heartbeat interval or median heart rate as compared to the patient's baseline heartbeat interval or median heart rate measured prior to treatment;
• an abnormal blood coagulation measure, wherein said treatment is effective to significantly improve an abnormal patient blood coagulation measure as compared to the patient's baseline blood coagulation as measured prior to treatment;
• an abnormal blood cell measure, wherein said treatment is effective to significantly improve an abnormal patient blood cell measure as compared to the patient's baseline blood cell measure as measured prior to treatment;
• an abnormal adrenocorticotropic hormone (ACTH) or pro-opiomelanocortin (POMC) level, wherein said treatment is effective to significantly improve an abnormal patient ACTH or POMC level as compared to the patient's baseline ACTH or POMC level as measured prior to treatment;
• improve quality of life in a Cushing's patient, wherein said treatment is effective to significantly improve patient quality of life as compared to the patient's baseline quality of life as measured prior to treatment;
• improve cognition in a Cushing's patient, wherein said treatment is effective to significantly improve patient cognition as compared to the patient's baseline cognition as measured prior to treatment;
• lessen patient depression, as measured by a psychological measure of depression, wherein said treatment is effective to significantly reduce patient depression as compared to the patient's baseline depression as measured prior to treatment;
• whereby the patient suffering from hypercortisolemia and a symptom or comorbidity thereof is treated and the symptom or comorbidity is improved.